Gufic Biosciences Q1 FY27 Profit Rises 85.5% to ₹22.46 Crore

For Q1 FY27 ended June 30, 2026, Gufic Biosciences Limited reported profit after tax of ₹22.46 crore, up 85.5% year on year. Revenue from operations rose 14.9% to ₹260.8 crore, while EBITDA increased 42.2% to ₹47.2 crore. The results indicate improved operating leverage and a higher EBITDA margin.

What did Gufic Biosciences report for Q1 FY27?

Gufic Biosciences reported total revenue of ₹260.8 crore for Q1 FY27, compared with ₹226.9 crore in Q1 FY26. The increase of ₹33.9 crore represented year-on-year growth of 14.9%. Revenue was also above the ₹252.1 crore reported in Q4 FY26.

EBITDA rose to ₹47.2 crore from ₹33.2 crore a year earlier. This was a 42.2% increase, materially faster than revenue growth. EBITDA margin expanded to 18.09% from 14.60% in Q1 FY26, a rise of 349 basis points. Profit before tax was ₹30.1 crore, compared with ₹16.3 crore in the year-earlier quarter.

The company said profit after tax rose 85.5% year on year to ₹22.46 crore. Management attributed the improvement to better operating leverage, margin expansion and progress in the Indore manufacturing facility. The available earnings summary does not provide a detailed break-up of costs or tax movements behind the profit increase.

How did Gufic Biosciences' margins improve?

Gufic's EBITDA margin improved to 18.09% in Q1 FY27 from 14.60% in Q1 FY26, as EBITDA growth outpaced the increase in revenue. The margin was also above 17.74% in Q4 FY26, showing a sequential improvement of 35 basis points.

Operating leverage generally becomes visible when fixed manufacturing and operating costs are spread over higher sales. In Gufic's case, the reported figures show that a 14.9% rise in revenue was accompanied by 42.2% EBITDA growth. This relationship is the principal numerical support for management's comment on improved operating efficiency.

The company reported EBITDA of ₹44.7 crore in Q4 FY26 and ₹152.9 crore for FY26. For context, its FY26 total revenue was ₹940.5 crore, compared with ₹819.8 crore in FY25. FY26 EBITDA margin was 16.26%, below the Q1 FY27 margin but above the 14.60% margin recorded in the comparable first quarter of the previous year.

What is the status of Gufic's Indore manufacturing facility?

Gufic said its Indore plant is fully operational and that capacity utilisation is rising. Management expects utilisation to move towards 40% to 45% by the end of the financial year, according to the Q1 FY27 earnings call summary.

The facility's operational status matters because increased utilisation can support the company's manufacturing capacity and may contribute to operating leverage. However, the company did not disclose the plant's total capacity, specific products made at the site, capital expenditure, or revenue contribution in the material provided.

Management's utilisation target is therefore a key operational measure to monitor rather than a disclosed earnings forecast. The Q1 result establishes that margins improved during the quarter, but it does not quantify how much of that improvement was directly generated by the Indore unit.

Why do the Q1 FY27 results matter to investors?

The Q1 FY27 results matter because Gufic delivered revenue growth alongside a larger increase in EBITDA and profit after tax. The 85.5% rise in reported PAT to ₹22.46 crore and the 349-basis-point EBITDA-margin expansion are the clearest indicators of the quarter's financial improvement.

For investors, the comparison with Q4 FY26 also provides a current operating reference. Revenue rose from ₹252.1 crore in Q4 FY26 to ₹260.8 crore in Q1 FY27, while EBITDA increased from ₹44.7 crore to ₹47.2 crore. The EBITDA margin improved from 17.74% to 18.09% over the same period.

The company has disclosed a Q2 FY27 earnings conference call scheduled for November 16, 2026, at 4:30 pm IST. That update is expected to cover business background, prospects and financial performance, according to the call intimation. It will be relevant for assessing whether the Q1 margin level and Indore utilisation progress are sustained.

How does Q1 FY27 compare with Gufic's recent financial record?

Gufic's Q1 FY27 revenue of ₹260.8 crore was higher than its ₹231.1 crore revenue in Q3 FY26 and ₹230.4 crore in Q2 FY26, based on the investor presentations provided. It was also above Q4 FY26 revenue of ₹252.1 crore.

The latest quarter followed FY26 total revenue of ₹940.5 crore and EBITDA of ₹152.9 crore. In FY25, the company had reported revenue of ₹819.8 crore and EBITDA of ₹138.6 crore. These annual figures show that Gufic entered FY27 after a year in which revenue increased, while Q1 FY27 showed a further step-up in quarterly EBITDA margin.

The available information does not provide a share-price movement, valuation data, product-level sales split, or guidance for FY27. As a result, the reported financial and operational data are more useful for tracking quarterly execution than for drawing conclusions about future performance.

Conclusion

Gufic Biosciences began FY27 with revenue of ₹260.8 crore, EBITDA of ₹47.2 crore and PAT of ₹22.46 crore. EBITDA margin improved to 18.09%, while management cited operating leverage, margin expansion and the operational Indore plant as factors supporting the quarter's performance.

The next disclosed event is Gufic's Q2 FY27 earnings conference call on November 16, 2026. Investors will watch for updated revenue and margin data, as well as management's progress towards its stated 40% to 45% Indore capacity-utilisation target by the end of the financial year.